Management of Mycobacterium Avium Complex (MAC) Disease

Diagnostic Approach

The American Thoracic Society recommends obtaining monthly sputum samples for AFB smear and culture to establish whether this represents active MAC lung disease versus colonization 1, 2
Blood cultures are NOT routinely indicated unless the patient is severely immunocompromised, as pulmonary MAC rarely causes disseminated disease in immunocompetent hosts 3
One positive sputum culture combined with compatible clinical and radiographic findings is sufficient for diagnosis in the context of prior MAC history 1

High-resolution CT (HRCT) chest scan is essential to assess for cavitary disease, nodular bronchiectatic pattern with tree-in-bud opacities, new infiltrates or progression from prior imaging 1, 2, 5, 6
Hemoptysis in MAC patients often correlates with cavitary lesions or severe bronchiectasis 6, 1

The American College of Chest Physicians recommends a three-drug regimen for non-cavitary nodular/bronchiectatic disease, including clarithromycin or azithromycin, ethambutol, and rifampin 1, 2, 5
For cavitary or severe disease, a daily regimen is recommended, including clarithromycin or azithromycin, ethambutol, rifampin, and consider adding parenteral amikacin or streptomycin 1, 2, 5
At least three drugs must be used to prevent resistance 1, 2, 5

Obtain monthly sputum AFB smears and cultures throughout treatment 1, 2
Expect sputum conversion to negative within 12 months on macrolide-containing regimens 1, 2
Clinical improvement should occur within 3-6 months 1, 2
Continue therapy for 12 months AFTER sputum culture conversion (total treatment often 15-18 months) 1, 2, 5

Macrolide resistance is catastrophic and associated with treatment failure and increased mortality 1, 2, 5
Patients respond best to treatment the first time—getting the initial regimen right is crucial 1, 2
Distinguishing colonization from disease is crucial, especially in previously treated MAC patients 1, 2